Entera Bio (ENTX) Stock Price, News & Analysis

Company Overview

Entera Bio Ltd. is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company’s proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence.

Entera Bio’s lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism. The company has also evaluated applications of its platform in other therapeutic areas.

Founded in 2010 and headquartered in Jerusalem, Israel, Entera Bio conducts its development activities for international markets, including the United States. The company is led by David Amsellem, its co-founder and chief executive officer. Entera Bio’s shares trade on the Nasdaq under the symbol ENTX.

Key Stats

• Today's Range: $2.82 to $2.90
• 50-Day Range: $2.69 to $3.92
• 52-Week Range: $0.91 to $4.20
• Volume: 100,699 shs
• Average Volume: 449,380 shs
• Market Capitalization: $497.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.60
• Consensus Rating: Moderate Buy

Entera Bio Stock Analysis - MarketRank™

Entera Bio scored higher than 72% of companies evaluated by MarketBeat, and ranked 177th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Entera Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Entera Bio has a consensus price target of $9.60, representing about 235.7% upside from its current price of $2.86.

Amount of Analyst Coverage

Entera Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Entera Bio are expected to grow in the coming year, from ($0.40) to ($0.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Entera Bio is -8.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Entera Bio is -8.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Entera Bio has a P/B Ratio of 9.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.82% of the float of Entera Bio has been sold short.

Short Interest Ratio / Days to Cover

Entera Bio has a short interest ratio ("days to cover") of 3.57, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Entera Bio has recently increased by 44.68%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Entera Bio does not currently pay a dividend.

Dividend Growth

Entera Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.15

News Sentiment

Entera Bio has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Entera Bio this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for ENTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

2 people have added Entera Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Entera Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.57% of the stock of Entera Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

14.11% of the stock of Entera Bio is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ENTX
• CIK: 1638097
• Web: www.enterabio.com
• Phone: (722) 532-7151
• Fax: N/A
• Employees: 21
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Entera Bio: $9.60
• High Price Target: $11.00
• Low Price Target: $9.00
• Potential Upside/Downside: +235.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -147.19%
• Return on Assets: -103.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.98
• Quick Ratio: 8.98

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.29 per share
• Price / Book: 9.86

Miscellaneous

• Outstanding Shares: 173,922,000
• Free Float: 155,538,000
• Market Cap: $497.42 million
• Optionable: Optionable
• Beta: 1.40